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Deficiency of adenosine deiminase 2 (DADA2) syn-
drome is a recently described autosomal recessively
inherited autoinflammatory disorder associated with mis-
sense mutations in CECR1 gene. Clinical manifestations
include early onset stroke, livedoid vascular changes, and
a vasculopathy mimicking classical polyarteritis nodosa
(cPAN) characterized by microaneurysms and associated
inflammatory findings. We herein describe a male patient
with homozygous G47R mutation in the CECR1 gene,
whose inflammatory findings did not respond to immu-
nosuppressive treatments and recombinant IL-1 receptor
antagonist, anakinra injections, but controlled with
adalimumab.
Case report
A 20-year-old male patient presented to our clinic two
years ago with findings of cPAN. He had a consangui-
neous family from South East Turkey without any other
affected individuals. He started to experience a skin rash
at the age of 5, and he had a history of polypectomy fol-
lowing a rectal bleeding and then an explorative laparot-
omy due to skin rash, abdominal pain, and fever, with the
diagnosis of Henoch Schönlein purpura at the age of 7.
He also had hepatosplenomegaly, and he continued to
experience 2-3 day lasting abdominal pain, especially
after cold exposure until the age of 16. A skin biopsy
revealed livedoid vasculitis. He also had a history of facial
paralysis 3 years ago, and a sudden vision loss due to
right retinal artery occlusion and hypertension 2 year
ago. He was admitted to our hospital because of microa-
neurysms in cranial and renal arteries, with signs of renal
infarcts as well as findings of mononeuritis multiplex and
systemic inflammation. He was first diagnosed with
familial Mediterranean fever (FMF) associated cPAN, and
started to receive corticosteroids along with 3 courses of
500mg cyclophosphamide pulses. He then continued to
receive azathioprine. MEFV gene screening revealed no
exon 10 variations compatible with FMF diagnosis, and
after the description of DADA2 syndrome, he was
screened for CECR1 mutations, which revealed homozy-
gous G47R mutation. During follow-up, he experienced
transient ischemic attacks, and his acute phase response
could not be controlled with cortiocoteroids and 2mg/kg
azathioprine. After addition of 100 mg/day anakinra to
his treatment, his acute phase response partially reduced
and clinical findings remained stable for nearly 3 months,
and increased doses of 200 mg/day did not provide addi-
tional help. However, switching his treatment to adalimu-
mab dramatically reduced his CRP and ESR levels to
normal limits.
Conclusion
The pathogenesis and inflammatory characteristics of
CECR1 mutation associated DADA2 syndrome and its vas-
cular findings have not been elucidated yet, and a favorable
response of our patient with DADA2 to adalimumab but
not to anakinra treatment may provide insights to its
inflammatory mechanisms.
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